Recombinant humanized XVII type collagen as well as preparation method and application thereof

By designing and expressing recombinant humanized XVII collagen, the problems of difficult preparation and poor biocompatibility in the prior art are solved, and efficient and safe collagen preparation is achieved, which is used to promote cell proliferation and tissue regeneration, and is suitable for Medical and cosmetics fields.

CN118955691AActive Publication Date: 2024-11-15HEBEN (ZHUJI) BIOTECHNOLOGY CO LTD +1

Patent Information

Application Number
CN202411465305.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-21
Publication Date
2024-11-15
Estimated Expiration
2044-10-21

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prepare and apply type XVII collagen, which leads to accelerated skin aging, and is difficult to recombinant technology, with low feasibility of animal extraction, and there is a risk of biocompatibility and rejection.

Method used

By designing and expressing recombinant humanized XVII collagen, expressing and purifying using E. coli cells, ensuring sequence identity and biological activity, reducing the introduction of heterologous amino acid residues, and using peptide bond ligation and affinity tagging technology to improve stability and Biocompatibility.

Benefits of technology

It has achieved efficient preparation of recombinant humanized XVII collagen, with 100% sequence identity, promotes cell proliferation, adhesion and tissue regeneration, reduces the risk of sensitization, and is suitable for medical devices and cosmetics and other fields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955691A_ABST
    Figure CN118955691A_ABST
Patent Text Reader

Abstract

The invention provides recombinant humanized XVII type collagen as well as a preparation method and application thereof, and relates to the technical field of biology. The recombinant humanized XVII type collagen provided by the invention comprises a basic repetitive unit, and the amino acid sequence of the basic repetitive unit is as shown in SEQ ID NO. 1; the number of the basic repeating units is at least one, and when the number of the basic repeating units is larger than or equal to 2, the adjacent basic repeating units are connected through peptide bonds. The recombinant humanized XVII type collagen has 100% sequence identity with human collagen, and has no rejection and sensitization risks; the hydrogel has good cell proliferation promoting activity, cell adhesion promoting activity and tissue regeneration and repair promoting capability, and is good in biocompatibility; and the water-soluble polymer is good in water solubility, high in stability, not easy to degrade and high in safety, and can be applied to the industrial fields of medical instruments or cosmetics and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a recombinant humanized type XVII collagen and a preparation method and application thereof. Background Art

[0002] Type XVII collagen is a type II transmembrane protein that plays a key role in the adhesion junctions between epidermal and epithelial cells and the basement membrane. The intracellular domain of type XVII collagen interacts with β4 integrin, vimentin, and BP230, while its extracellular domain interacts with α6 integrin and laminin 332 of the basement membrane, together forming hemidesmosome structures.

[0003] Competition between epidermal stem cells driven by type XVII collagen is the key to delaying or reversing skin aging. Degradation of type XVII collagen leads to a decrease in the self-renewal ability of epidermal cells. Studies have reported that type XVII collagen maintains the structural integrity of the skin. Epidermal stem cells with high expression of type XVII collagen are firmly anchored to the basement membrane and squeeze out nearby cells with low expression of type XVII collagen through symmetrical division. Ultraviolet radiation and oxidative stress induce increased proteases, which degrade type XVII collagen. The hemidesmosome structure connecting the basement membrane and epidermal cells is destroyed, the epidermal cell layer falls off, and fibroblasts and melanocytes decrease (reference: Nature. 2019 Apr;568(7752):344-350.).

[0004] At present, the collagen used in the market includes animal-derived collagen and recombinant humanized collagen. Compared with animal-derived collagen, recombinant humanized collagen not only has better biological activity, biocompatibility and water solubility, but also has low pathogen risk and is easy to produce on a large scale. However, type XVII collagen is scarce and the feasibility of animal extraction is low, so recombinant technology is needed to achieve its expression. Since natural type XVII collagen is composed of 1497 amino acids, it is currently difficult to prepare full-length type XVII collagen, and it is usually chosen to express its specific functional domains to achieve related functions.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The first object of the present invention is to provide a recombinant humanized type XVII collagen to solve the above problems.

[0007] The second object of the present invention is to provide a nucleic acid molecule.

[0008] The third object of the present invention is to provide a carrier.

[0009] A fourth object of the present invention is to provide a cell.

[0010] The fifth object of the present invention is to provide a method for preparing the above-mentioned recombinant humanized type XVII collagen.

[0011] The sixth object of the present invention is to provide the use of the above-mentioned recombinant humanized type XVII collagen in medical devices, cosmetics or culture media.

[0012] In order to achieve the above objectives, the following technical solutions are adopted: In a first aspect, the present invention provides a recombinant humanized type XVII collagen, wherein the recombinant humanized type XVII collagen comprises a basic repeating unit, and the amino acid sequence of the basic repeating unit is shown in SEQ ID NO.1; The number of the basic repeating units is at least 1. When the number of the basic repeating units is greater than or equal to 2, adjacent basic repeating units are connected by peptide bonds.

[0013] As a further technical solution, the number of the basic repeating units is 3; The amino acid sequence of the recombinant humanized type XVII collagen is shown in SEQ ID NO.2.

[0014] In a second aspect, the present invention provides a nucleic acid molecule encoding the recombinant humanized type XVII collagen.

[0015] As a further technical solution, the nucleotide sequence of the nucleic acid molecule is shown as SEQ ID NO.3.

[0016] In a third aspect, the present invention provides a vector, which carries the nucleic acid molecule.

[0017] In a fourth aspect, the present invention provides a cell, wherein the cell carries the nucleic acid molecule, or contains the vector, or expresses the recombinant humanized type XVII collagen.

[0018] As a further technical solution, the cell comprises Escherichia coli.

[0019] In a fifth aspect, the present invention provides a method for preparing recombinant humanized type XVII collagen, comprising: using the cells to express the recombinant humanized type XVII collagen, and then preparing the recombinant humanized type XVII collagen after separation and purification.

[0020] In a sixth aspect, the present invention provides the use of recombinant humanized type XVII collagen in medical devices, cosmetics or culture media.

[0021] Compared with the prior art, the present invention has the following beneficial effects: (1) The recombinant humanized type XVII collagen fragment provided by the present invention has 100% sequence identity with human collagen and strictly adheres to the Gly-Xaa-Yaa repeating sequence pattern, without the introduction of heterologous amino acid residues, and has no risk of rejection or sensitization.

[0022] (2) The recombinant humanized type XVII collagen fragment provided by the present invention has good biological activity, including promoting cell proliferation activity, promoting cell adhesion activity, promoting tissue regeneration and repair activity, and has good biocompatibility.

[0023] (3) The recombinant humanized type XVII collagen fragment provided by the present invention has good water solubility, high stability, is not easy to degrade, and has undergone strict endotoxin testing, thus avoiding all potential risks as much as possible, and can be widely used in industries such as medical devices or cosmetics. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 : Schematic diagram of the expression plasmid of recombinant humanized type XVII collagen PSQ2x3; Figure 2 : SDS-PAGE detection diagram of expression and purification of recombinant humanized type XVII collagen PSQ2x3, the theoretical molecular weight is about 44kDa; Figure 3 : SDS-PAGE detection of the recombinant humanized type XVII collagen PSQ2x3 digestion product, the theoretical molecular weight is about 26kDa; Figure 4 : SDS-PAGE detection of recombinant humanized type XVII collagen PSQ2x3 digestion product after Ni column de-tagged protein, the theoretical molecular weight is about 26kDa; Figure 5 : SDS-PAGE detection image of recombinant humanized type XVII collagen PSQ2x3 repeatedly passed through Q column to remove endotoxin, the theoretical molecular weight is about 26kDa; Figure 6 :Stability of recombinant humanized type XVII collagen PSQ2x3 stored at 55°C; Figure 7: Recombinant humanized type XVII collagen PSQ2x3 promotes HSF cell proliferation; Figure 8 : Recombinant humanized type XVII collagen PSQ2x3 promotes HSF cell adhesion; Fig. 9 : Recombinant humanized type XVII collagen PSQ2x3 promotes HSF cell migration; Fig.10 : Recombinant humanized type XVII collagen PSQ2x3 has no hemolytic effect on mouse blood cells; Fig.11 : Recombinant humanized type XVII collagen PSQ2x3 did not affect the tube-forming ability of HUVEC cells; Fig.12 : Subcutaneous injection of recombinant humanized type XVII collagen PSQ2x3 into mice did not cause sensitization; Fig.13 :Recombinant humanized type XVII collagen PSQ2x3 promotes skin wound tissue repair in mice; Fig.14 : H&E staining and MASSON staining of skin tissue of mouse skin wounds treated with recombinant humanized type XVII collagen PSQ2x3. DETAILED DESCRIPTION

[0026] The embodiments of the present invention will be described in detail below in conjunction with the embodiments and examples, but it will be appreciated by those skilled in the art that the following embodiments and examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of the present invention. If specific conditions are not specified, proceed according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0027] The term "vector" refers to a nucleic acid delivery vehicle into which nucleotides can be inserted. When a vector can express the protein encoded by the inserted nucleotides, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell.

[0028] The vector is well known to those skilled in the art, including but not limited to: plasmid; phagemid; cosmid; artificial chromosome, such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); bacteriophage such as λ phage or M13 phage and animal virus, etc. Animal viruses that can be used as vectors include but are not limited to retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (such as herpes simplex virus), poxvirus, baculovirus, papillomavirus, papillomavirus. In some embodiments, the vector of the present invention contains regulatory elements commonly used in genetic engineering, such as enhancers, promoters, internal ribosome entry sites (IRES) and other expression control elements (such as transcription termination signals, or polyadenylation signals and poly U sequences, etc.).

[0029] As used herein, the expressions "cell", "cell line" and "cell culture" are used interchangeably, and all such designations include progeny. Progeny may not necessarily be identical to the primary cell, e.g., differ in morphology and / or in genomic DNA, due to natural, accidental or deliberate mutation. "Transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom.

[0030] In the present invention, the screened protein sequence is from human type 17 collagen COL17A1, and the reference sequence number of the protein in NCBI is: NP_000485, for details, refer to: https: / / www.ncbi.nlm.nih.gov / protein / NP_000485.3.

[0031] The specific sequence of NP_000485 is shown in SEQ ID NO.4:

[0032] The amino acid sequence selected by the present invention is extracted from the above sequence. In the first aspect, the present invention provides a recombinant humanized type XVII collagen, the recombinant humanized type XVII collagen comprises a basic repeating unit (denoted as PSQ2), the amino acid sequence of the basic repeating unit is shown in SEQ ID NO.1: GSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQGPKGQKGSVGDPGMEGPMGQRGREGPMGPRGEAGPPGSGEKGERGAAGEPGPHGPP (SEQ ID NO. 1).

[0033] The number of the basic repeating units is at least 1. When the number of the basic repeating units is greater than or equal to 2, adjacent basic repeating units are connected by peptide bonds.

[0034] The inventors have found through research that the recombinant humanized type XVII collagen fragment provided by the present invention has good biological activity, including promoting cell proliferation activity, promoting cell adhesion activity, promoting tissue regeneration and repair, and good biocompatibility; the recombinant humanized type XVII collagen fragment has good water solubility, high stability, is not easy to degrade, is safe to use, and can be applied to industries such as medical devices or cosmetics.

[0035] In some optional embodiments, the number of the basic repeating units is 3; The amino acid sequence of the recombinant humanized type XVII collagen (denoted as PSQ2x3) is shown in SEQ ID NO.2: GSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQGPKGQKGSVGDPGMEGPMGQRGREGPMGPRGEAGPPGSGEKGERGAAGEPGPHGPPGSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQGPKGQKGSVGDP GMEGPMGQRGREGPMGPRGEAGPPGSGEKGERGAAGEPGPHGPPGSPGPPKGDMGSPGPKGDRGFPGTPGIPGPLGHPGPQGPKGQKGSVGDPGMEGPMGQRGREGPMGPRGEAGPPGSGEKGERGAAGEPGPHGPP (SEQ ID NO.2).

[0036] In some optional embodiments, an affinity tag is connected to the N-terminus of the recombinant humanized type XVII collagen.

[0037] Affinity tags are a technology that uses gene cloning to fuse polypeptides, protein domains, or even complete proteins with target proteins to achieve expression, purification, detection, and tracing of target proteins. Protein tags can be roughly divided into three categories according to their functions: detection tags, expression and purification tags, and tracing tags. Currently, commonly used expression and purification tags include: His, GST, etc.

[0038] In a second aspect, the present invention provides a nucleic acid molecule encoding the recombinant humanized type XVII collagen.

[0039] Nucleic acid molecules are the general term for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), are biomacromolecules polymerized by many nucleotide monomers, and are one of the most basic substances of life. Nucleotide sequence refers to the order of arrangement of bases in DNA or RNA. Nucleic acid molecules contain cDNA, and in some cases, nucleic acid molecules can be modified for use in vectors of the present invention, such as for codon optimization. In some cases, for the purpose of cloning into a vector, the sequence can be designed to contain a terminal restriction site sequence. Nucleic acid molecules can be obtained from a variety of sources, such as by polymerase chain reaction (PCR) amplification of coding nucleic acids separated in one or more given cells or from the one or more given cells.

[0040] In a specific embodiment, the above nucleic acid molecules can be optimized according to the codon preference of the host cell and then artificially synthesized into gene fragments. It should be understood that nucleic acid molecules that can be translated into the above amino acid sequences are within the scope of protection of the present invention.

[0041] In some optional embodiments, the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO.3: (SEQ ID NO.3).

[0042] In a third aspect, the present invention provides a vector, which carries the nucleic acid molecule.

[0043] In a fourth aspect, the present invention provides a cell, wherein the cell carries the nucleic acid molecule, or contains the vector, or expresses the recombinant humanized type XVII collagen.

[0044] In some optional embodiments, the cells include but are not limited to Escherichia coli, or other cells well known to those skilled in the art.

[0045] In a fifth aspect, the present invention provides a method for preparing recombinant humanized type XVII collagen, comprising: using the cells to express the recombinant humanized type XVII collagen, and then preparing the recombinant humanized type XVII collagen after separation and purification.

[0046] In a sixth aspect, the present invention provides the use of recombinant humanized type XVII collagen in medical devices, cosmetics or culture media.

[0047] The inventors have found that the recombinant humanized type XVII collagen provided by the present invention has good safety, and has the effects of promoting cell proliferation, cell adhesion, cell migration, wound healing, tissue repair and angiogenesis, and can be used as medical dressings, skin repair and regeneration materials, oral mucosa repair and regeneration materials, cervical mucosa repair and regeneration materials, plastic surgery materials, tissue injection filling, cosmetic raw materials, cleaning product raw materials, etc.

[0048] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.

[0049] Embodiment 1 This embodiment is a method for preparing a recombinant humanized type XVII collagen fragment, taking PSQ2x3 as an example (the amino acid sequence is shown in SEQ ID NO.2, and the nucleotide sequence is shown in SEQ ID NO.3), comprising the following steps: (1) Construction of a recombinant expression plasmid containing a recombinant humanized type XVII collagen fragment: Based on the nucleotide sequence SEQ ID NO.3, Nanjing GenScript Biotechnology Co., Ltd. was commissioned to synthesize the gene fragment. The synthesized gene fragment was inserted into the pET-32a(+) vector through the KpnⅠ and XhoⅠ restriction sites to obtain a recombinant expression plasmid. The specific recombinant expression plasmid is as follows: Figure 1 shown.

[0050] (2) The constructed recombinant expression plasmid was transferred into E. coli competent cells BL21 (DE3) (Invitrogen). The specific process is as follows: a. Take 100 ng of the recombinant expression plasmid and add it to 100 μl of competent cells, mix gently, and incubate on ice for 30 min; b. Heat shock the competent cells mixed with the recombinant plasmid at 42°C for 1 min, and then incubate on ice for 3 min; c. Add 900 μl of LB medium (10 g / L sodium chloride, 10 g / L tryptone, 5 g / L yeast extract) to the mixture and culture at 37°C, 200 rpm for 1 h; d. Centrifuge the resuscitated bacterial solution at 8000 rpm for 3 min, remove an appropriate volume of supernatant, resuspend the bacteria and spread them on an LB plate containing ampicillin sodium; e. Incubate the plate inverted at 37°C for about 12 h to grow a single clone of appropriate size.

[0051] (3) Induce the obtained E. coli genetically engineered bacteria to produce recombinant type XVII humanized collagen fragments. The specific process is: a. Pick the monoclonal colony on the LB plate and put it into 5 ml of LB medium containing sodium ampicillin, and culture it at 37°C with shaking overnight; b. Take the bacterial liquid and inoculate it into LB medium containing sodium ampicillin at a 1% inoculum, and continue to culture it at 37°C with shaking until the OD 600 c. Add inducer IPTG to the bacterial solution to a final concentration of 0.5 mM, then incubate at 16°C with shaking for 16-24 hours.

[0052] (4) Recover, digest and purify recombinant type XVII humanized collagen fragments. The specific process is as follows: a. Centrifuge the induced bacterial solution at 4°C, 4000rpm for 20min, collect and wash the bacterial precipitate; b. Resuspend the bacterial precipitate in lysis buffer (20mM imidazole, 500mM sodium chloride, 20mM PB, pH 7.4), and use a high-pressure homogenizer to break the cells; c. Centrifuge the broken bacterial solution at 4°C, 12000rpm for 60min, and collect the supernatant; d. Load the supernatant onto the nickel column, and then use 10 column volumes of equilibration buffer (20mM imidazole, 500mM sodium chloride, 20mM PB, pH 7.4) to elute the impurities; e. Use washing buffer (400mM imidazole, 500mM NaCl, 20mM PB, pH 7.4) to elute the target protein. The specific protein expression and purification conditions are as follows. Figure 2 f. The purified target protein was replaced with a tangential flow ultrafiltration system, and an appropriate amount of TEV protease was added for overnight digestion at 4°C. The specific digestion conditions are shown in Figure 3 As shown; g. The protein solution after cleavage is loaded onto the nickel column again, and the flow-through is collected to remove TEV protease and non-collagen parts. The specific situation of the impurity removal step is as follows. Figure 4 shown.

[0053] (5) Remove endotoxins. The specific process is as follows: a. Desalt the protein solution obtained in step (4) and replace it with a solution (20mM Tris-base, pH 7.8); b. Load the protein sample onto the Q column and collect the flow-through to remove endotoxins; c. Repeat step b until the endotoxin content is reduced to the acceptable range. The specific removal situation is as follows: Figure 5 shown.

[0054] Embodiment 2 SDS-PAGE analysis of recombinant humanized type XVII collagen fragments This example uses SDS-PAGE to detect the recombinant humanized type XVII collagen fragment (PSQ2x3) prepared in each step of Example 1 and determine the molecular weight range. It includes the following steps: (1) Take 15 μl of the protein stock solution prepared in each step of Example 1 (after washing the precipitate, take a small amount and resuspend it in the same volume of PBS), add 3 μl of 6× protein loading buffer (Quanshijin Biotechnology Co., Ltd.), mix well, and incubate in a 100°C water bath for 10 min; (2) Take 10 μl of sample solution and protein marker (New Saimei Biotechnology Co., Ltd.) and load them into the SDS-PAGE gel wells. Run electrophoresis at 120 V for about 2 h. (3) Remove the protein gel, rinse it with water three times, and then stain it with protein staining solution (Biyuntian Biotechnology Co., Ltd.) for 20 minutes. Then rinse it with water overnight. The electrophoresis results are as follows: Figure 2-Figure 5 shown.

[0055] Embodiment 3 In this example, the recombinant humanized type XVII collagen PSQ2x3 prepared in Example 1 was freeze-dried in a vial, dissolved in ultrapure water to form a 5 mg / ml protein solution, and stored in an incubator at 55° C. The sample conditions were observed on days 0, 1, 2, and 3, and some samples were taken out. The stability of the recombinant protein PSQ2x3 was detected by SDS-PAGE electrophoresis.

[0056] The experimental results show that when PSQ2x3 is stored at 55°C for 1, 2, and 3 days, the protein solution is clear without precipitation, and the brightness of the PSQ2x3 band detected by SDS-PAGE electrophoresis does not change significantly, and no degradation occurs. Figure 6 shown.

[0057] Embodiment 4 This example detects the cell proliferation rate of the recombinant humanized type XVII collagen (PSQ2x3) prepared in Example 1, and includes the following steps: (1) Normally culture HSF cells within 10 generations to about 90%; (2) Digest the cells and seed 5,000 cells per well of a 96-well plate and allow them to adhere overnight. (3) The next day, culture medium containing target concentrations of collagen (0.1, 0.5, 1 mg / ml) was prepared according to the experimental plan. At the same time, a positive control of human type III collagen (Collagen III, derived from human embryos, Advanced BioMatrix) was set up.

[0058] (4) Take out the 96-well plate, change the medium and put it back to continue culturing; (5) After 24 hours, the cell proliferation was detected using CCK8 kit.

[0059] The results are as follows Figure 7 As shown, the mean and standard error based on 3 parallel experiments are plotted.

[0060] Figure 7 The results showed that the recombinant humanized type XVII collagen PSQ2x3 prepared in Example 1 had no significant effect on cell survival at low concentrations (<0.1 mg / ml). When the collagen concentration was increased to 0.5 mg / ml, cell proliferation was significantly increased compared with the negative control group, while human type III collagen showed an inhibitory effect on cell proliferation, and the higher the concentration, the stronger the inhibitory effect.

[0061] Embodiment 5 This example detects the cell adhesion promoting activity of the recombinant humanized type XVII collagen fragment (PSQ2x3) prepared in Example 1. The steps include: (1) Prepare a buffer solution containing target concentrations (0.1, 1, 10, 100, 1000 μg / ml) of collagen in PBS; (2) According to the experimental protocol, 100 μl of collagen buffer of different concentrations was added to the 96-well plate, and PBS without collagen was added to two columns as a control, and the plates were coated at 4°C overnight. (3) The next day, take out the 96-well plate, remove the coating solution, add 100 μl of PBS containing 5% BSA, and block at 37°C for 1 h. (4) Before seeding cells, take out the 96-well plate, wash it once with PBS, seed 20,000 HSF cells in each well, and use 90 μl of cell suspension (cells diluted with serum-free medium) in each well; (5) After 20-40 minutes, depending on the cell adhesion, remove the 96-well plate and leave one control group untreated. Remove the supernatant from the other control group and the remaining experimental groups and wash once with PBS. (6) Add 100 μl of serum-free culture medium containing CCK8 (culture medium: CCK8 = 9:1). For the untreated control group, directly add 10 μl of CCK8.

[0062] The results are as follows Figure 8 As shown, the mean and standard error based on 3 parallel experiments are plotted.

[0063] Figure 8 The results showed that the recombinant humanized type XVII collagen PSQ2x3 prepared in Example 1 had a good cell adhesion promoting property when the concentration reached 1 μg / ml, and the cell adhesion rate was significantly improved compared with the control group PBS. However, as the collagen concentration further increased, the cell adhesion rate did not show a significant improvement.

[0064] Embodiment 6 This example detects the cell migration promoting effect of the recombinant humanized type XVII collagen (PSQ2x3) prepared in Example 1. The steps include: (1) Use PBS to prepare a buffer solution containing the target concentration (50 μg / ml) of collagen; (2) According to the experimental protocol, add 1 ml of collagen buffer (50 μg / ml) to the 12-well plate and coat overnight at 4°C; (3) The next day, take out the 12-well plate, remove the supernatant, add PBS containing 5% BSA, and block at 37°C for 1 h. (4) After blocking, wash twice with PBS and dry at 37°C; (5) After drying, place the cells in the ibidi scratch insert (four chambers), add 20,000 cells to each chamber, and culture in a 37°C incubator overnight; (6) On the second day, take out the 12-well plate, remove the small insert, replace it with medium containing 1% FBS, and take photos; (7) After overnight culture, the cells were taken out and photographed, and the cell migration area was calculated using ImageJ software.

[0065] The results are as follows Fig. 9 As shown, 50 μg / ml collagen significantly promoted the migration of HSF cells compared with the control group.

[0066] Embodiment 7 In this example, the peptide coverage mass spectrometry was performed on the recombinant humanized type XVII collagen (PSQ2x3) prepared in Example 1. The test was completed by Sangon Biotech Co., Ltd. The experimental method and experimental results are as follows: (1) The protein sample was denatured with urea, reduced with DTT, and alkylated with IAA, and then digested with Trypsin protease at 37°C overnight; (2) The next day, the fragments after enzymatic digestion were collected, dried by centrifugation, and redissolved in Nano-LC mobile phase A (0.1% formic acid / water), loaded into bottles, and subjected to online LC-MS analysis.

[0067] (3) The sample was desalted and retained on a nanoViper C18 pre-column and then separated on a C18 reverse phase column.

[0068] (4) Mass spectrometry was performed using the ThermoFisher Orbitrap Fusion Lumos system (ThermoFisher, USA) combined with a Nano Easy-Spray ion source.

[0069] (5) The original raw data files acquired by mass spectrometry were processed and searched using PEAKS Studio 8.5 software.

[0070] (6) The database is the target protein sequence. The search parameters were set as follows: trypsin digestion, mass tolerance of primary mass spectrometry was 10 ppm, secondary mass spectrometry was 0.05 Da, and the maximum number of missed cuts of enzyme cleavage was 4; fixed modification: cysteine ​​iodoacetamidate; variable modification: protein N-terminal acetylation (Acetylation (Protein N-term)), asparagine / glutamine deamination (Deamidation (NQ)), methionine oxidation (Oxidation (M)), glutamic acid pyroglutamination (Pyro-glu), glutamine pyroglutamyl cyclization (Pyro-Gln), hydroxyproline modification (hydroxyproline).

[0071] The results are shown in the peptide coverage table. The coverage of the detected peptide segments is 100%, which is consistent with the theoretical sequence, proving that the recombinant protein PSQ2x3 was successfully expressed.

[0072] The peptide coverage results are as follows (i.e., the sequence shown in SEQ ID NO.2): .

[0073] Embodiment 8 In this example, a hemolytic experiment was performed on the recombinant humanized type XVII collagen (PSQ2x3) prepared in Example 1 to evaluate its safety. The specific method is as follows: (1) Take an appropriate amount of fresh mouse anticoagulated whole blood, centrifuge at 3000rpm for 10min, and discard the supernatant. Wash the red blood cells twice with saline, centrifuge at 3000rpm for 5min each time. Finally, resuspend the red blood cells in saline to prepare a 2% red blood cell suspension.

[0074] (2) Add 50 μl of 2% red blood cell suspension to 950 μl of PSQ2x3 solution (10, 100, 1000 μg / ml) in a centrifuge tube and mix gently. For the control group, replace the collagen solution with saline (negative control) and 0.1% Triton X-100 solution (positive control).

[0075] (3) Place all centrifuge tubes in a 37°C constant temperature water bath and incubate for 1 hour.

[0076] (4) After incubation, centrifuge at 3000 rpm for 5 min to observe whether hemolysis occurs.

[0077] This example evaluates the hemolytic activity of different concentrations of recombinant human collagen on red blood cells through a hemolytic experiment to verify the biosafety of PSQ2x3. Fig.10 As shown in the figure, all tested concentrations of PSQ2x3 (10, 100, 1000 μg / ml) did not cause significant hemolytic reactions. Compared with the negative control group (normal saline), there was no significant difference in the PSQ2x3 groups at each concentration, and it was significantly lower than the positive control group (Triton X-100). These results show that PSQ2x3 has no hemolytic effect on mouse red blood cells at the different concentrations tested, proving that it has good biocompatibility and blood safety.

[0078] Embodiment 9 In this example, the recombinant humanized type XVII collagen fragment (PSQ2x3) prepared in Example 1 was subjected to an endothelial cell (HUVEC cell) tube formation experiment to evaluate its safety. The specific method is as follows: (1) Dissolve 10, 100, and 1000 μg / ml PSQ2x3 in endothelial cell culture medium. Place the solution in a 37°C incubator for 12 hours to ensure that the collagen is fully dissolved and in a usable state.

[0079] (2) Take out Matrigel from the -20°C freezer and thaw it on ice overnight. Make sure Matrigel remains liquid on ice to prevent it from solidifying before use.

[0080] (3) While operating on ice, use a pipette to add 50 μl of Matrigel to each well of the 96-well plate. Place the 96-well plate with Matrigel in a 37°C incubator and incubate for 30 min to allow the Matrigel to solidify and form a stable gel layer.

[0081] (4) Resuspend the new generation HUVEC cells in endothelial cell culture medium containing PSQ2x3, and set the cell density to 2×10 5Add 100 μl of cell suspension to each Matrigel-coated well so that each well contains 2×10 4 cells. A control group (using only endothelial cell culture medium) was also set up. Three replicate wells were set up in each group to ensure the repeatability and accuracy of the experiment.

[0082] (5) Place the 96-well plate with cells seeded in a 37°C, 5% CO2 incubator for 12 h to promote cell attachment and tube formation.

[0083] (6) After incubation for 12 h, the tube-forming ability of HUVEC cells in each experimental group was observed under a microscope. The biocompatibility and potential toxicity of PSQ2x3 to cells were evaluated by comparing the tube-forming ability of the experimental group containing PSQ2x3 with that of the control group.

[0084] (7) The experiment was repeated three times to ensure the reliability of the results. The number of nodes formed in each group was quantitatively analyzed using image analysis software to evaluate the effect of PSQ2x3 on endothelial cell tube formation. By comparative analysis, it was determined whether PSQ2x3 had adverse effects on cells under in vitro conditions, thereby evaluating its safety.

[0085] The results showed that all tested concentrations of PSQ2x3 (10, 100, 1000 μg / ml) did not inhibit the tube-forming ability of HUVEC cells ( Fig.11 ). Compared with the control group (endothelial cell culture medium group), each concentration of PSQ2x3 group was able to support normal tubule formation. Microscopic observation and image analysis showed that the number of tube-forming nodes in each concentration of PSQ2x3 group was not significantly different from that in the control group, indicating that PSQ2x3 had no negative effect on the tube formation process of cells at these concentrations, and did not induce cell toxicity or inhibit cell function under this experimental condition.

[0086] Embodiment 10 In this example, the recombinant humanized type XVII collagen fragment (PSQ2x3) prepared in Example 1 was subjected to an in vivo sensitization experiment to detect the IgE level around the skin at the injection site to evaluate its sensitization: (1) The mice were randomly divided into three groups: an experimental group (PSQ2x3 solution + aluminum adjuvant), a positive control group (ovalbumin + aluminum adjuvant), and a negative control group (normal saline + aluminum adjuvant).

[0087] (2) On day 0, the back skin of the experimental group mice was disinfected with alcohol cotton balls, and then 100 μl of PSQ2x3 solution (10, 100, 1000 μg / ml) was injected subcutaneously. The positive control group was injected with 100 μl of ovalbumin solution, and the negative control group was injected with 100 μl of normal saline. Each solution was mixed with aluminum adjuvant. The injection site was on both sides of the midline of the mouse's back, alternating between left and right to reduce local stress response. The same injection process was repeated on day 14 to enhance the immune response.

[0088] (3) On day 28, after the mice were anesthetized with anesthetics, a small amount of skin tissue samples were taken from the skin around the injection site, ensuring that the epidermis and dermis were included. The collected skin tissue samples were placed in cold PBS solution and homogenized to extract tissue fluid. The specific IgE level in the serum of each group of mice was detected by enzyme-linked immunosorbent assay. The operation was performed according to the instructions of the kit, and finally the absorbance (OD value) was measured by spectrophotometer to quantify the serum IgE concentration.

[0089] The experimental results showed that all tested concentrations of PSQ2x3 (10, 100, 1000 μg / ml) did not cause significant increases in IL-6, TNF-α, and IgE levels ( Fig.12 ). These results indicate that PSQ2x3 did not induce significant allergic reactions in mice at the different concentrations tested. No significant increase in serum IL-6, TNF-α, and IgE levels was observed, further demonstrating that PSQ2x3 has good biocompatibility and low sensitization risk in vivo.

[0090] Embodiment 11 This example uses the recombinant humanized type XVII collagen fragment (PSQ2x3) prepared in Example 1 to promote mouse skin wound tissue repair. The experiment aims to verify the effectiveness of PSQ2x3 in accelerating wound healing and tissue repair. The specific method is: (1) Experimental mice Female BALB / c mice aged 6-8 weeks were selected and randomly divided into an experimental group (injected with 1 mg / ml PSQ2x3 solution) and a negative control group (injected with an equal amount of saline), with 6 mice in each group. After the mice were anesthetized with anesthetics, a circular full-thickness skin wound with a diameter of approximately 1 cm was made on the back of each mouse using sterile surgical tools to ensure that the skin barrier was completely destroyed, and the area around the wound was subsequently cleaned to prevent infection.

[0091] (2) 100 μl of the experimental solution was injected into the wound edge and surrounding subcutaneous area. The negative control group was injected with saline. After injection, the mice were housed individually to prevent licking and biting each other from interfering with wound healing.

[0092] (3) On days 0, 2, 5, 7, and 10 after injection, use a digital camera to photograph the wound healing process. Record the wound area and healing status. Before each photo, use a vernier caliper to measure the diameter and area of ​​the wound to quantify the wound healing rate.

[0093] (4) At the end of the experiment on the 10th day, skin tissue samples were taken from the wounds of mice in a painless manner after anesthesia. The collected tissue samples were fixed in formalin solution for 24 hours and then embedded in paraffin. The thickness of the embedded tissue sections was about 5 μm. The tissue sections were stained using the Masson staining method to facilitate the distinction and identification of collagen fibers. Immunofluorescence staining with CD31 was used to evaluate wound angiogenesis.

[0094] In this study, PSQ2x3 was injected locally into the skin wounds of mice to evaluate its effects on wound healing and tissue repair. Fig.13 As shown, compared with the injection of normal saline, the wound healing speed of the experimental group injected with PSQ2x3 was significantly accelerated at each time point. The wound area of ​​the PSQ2x3 group on the 2nd, 5th, 7th and 10th days was significantly smaller than that of the control group, indicating that PSQ2x3 effectively promoted wound healing. The histological analysis results on the 10th day further supported this conclusion. Masson staining showed that the deposition of collagen fibers in the wound tissue of the experimental group mice was significantly increased, and the distribution of collagen fibers was more dense and orderly compared with the negative control group. Immunofluorescence staining (CD31) results showed that ( Fig.14 ), the angiogenesis in the experimental group was significantly better than that in the control group, indicating that PSQ2x3 not only promoted collagen deposition but also enhanced angiogenesis in the wound area.

[0095] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A recombinant humanized type XVII collagen, characterized in that: The recombinant humanized type XVII collagen includes a basic repeating unit, and the amino acid sequence of the basic repeating unit is shown in SEQ ID NO.1; The number of the basic repeating units is at least 1. When the number of the basic repeating units is greater than or equal to 2, adjacent basic repeating units are connected by peptide bonds.

2. The recombinant humanized type XVII collagen according to claim 1, characterized in that The number of the basic repeating units is 3; the amino acid sequence of the recombinant humanized type XVII collagen is shown in SEQ ID NO.

2.

3. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the recombinant humanized type XVII collagen according to claim 1 or 2.

4. The nucleic acid molecule according to claim 3, characterized in that The nucleotide sequence of the nucleic acid molecule is shown as SEQ ID NO.

3.

5. A carrier, characterized in that The vector carries the nucleic acid molecule according to claim 3 or 4.

6. A cell, characterized in that The cell carries the nucleic acid molecule of claim 3 or 4, or contains the vector of claim 5, or expresses the recombinant humanized type XVII collagen of claim 1 or 2.

7. The cell according to claim 6, characterized in that The cells include Escherichia coli.

8. A method for preparing recombinant humanized type XVII collagen, characterized in that: include: The recombinant humanized type XVII collagen is expressed by the cells according to claim 6 or 7, and then separated and purified to prepare the recombinant humanized type XVII collagen.

9. Use of the recombinant humanized type XVII collagen according to claim 1 or 2 in medical devices, cosmetics or culture media.

Citation Information

Patent Citations

  • Recombinant human XVII type collagen, and preparation method and application thereof

    CN113185604A

  • An ELISA kit for detecting human BP180 IgG antibody and its application

    CN114236132B

  • Yeast recombinant XVII type humanized collagen and preparation method thereof

    CN116375847A

  • Yeast fermentation product filtrate containing recombinant 17-type human collagen

    CN116509764A

  • Recombinant X VII humanized collagen as well as preparation method and application thereof

    CN116751282A

Cited By

  • Method for biosynthesizing human body structural material XVII type collagen

    CN117843763A

  • Method for biosynthesis of human structural material type XVII collagen

    CN117843763B

  • High-activity recombinant human XVII type collagen as well as preparation method and application thereof

    CN119462899A

  • High-transdermal recombinant humanized XVII type collagen as well as preparation method and application thereof

    CN120623320A

  • Highly skin permeable recombinant humanized type xvii collagen and preparation method and application thereof

    CN120623320B